Aptose Biosciences, Inc.
APTO
APTO was delisted on the 1st of April, 2025.
25 hedge funds and large institutions have $3.25M invested in Aptose Biosciences, Inc. in 2023 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
4% more funds holding
Funds holding: 24 → 25 (+1)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
31% less capital invested
Capital invested by funds: $4.71M → $3.25M (-$1.46M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
+$573K |
| 2 |
AC
Annandale Capital
Dallas,
Texas
|
+$83.8K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$68.1K |
| 4 |
CA
Cetera Advisors
Denver,
Colorado
|
+$58.9K |
| 5 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$18K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$165K |
| 2 |
VC
Voss Capital
Houston,
Texas
|
-$67.9K |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$38.3K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$3.18K |
| 5 |
Morgan Stanley
New York
|
-$707 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
UBS Group
Zurich,
Switzerland
| $8 | -$118 | -1 | Closed |
|
27
Fidelity International
Hamilton,
Bermuda
| $4 | – | – | – |
|
28
National Bank of Canada
Montreal,
Quebec, Canada
| $3 | – | – | – |
|
|
29
Goldman Sachs
New York
| – | -$165K | -1,182 | Closed |
|
|
VC
30
Voss Capital
Houston,
Texas
| – | -$67.9K | -488 | Closed |
|
APTO Hedge Fund Activity: Q3 2023 in Review
25 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Aptose Biosciences, Inc. (APTO) for Q3 2023, worth a combined $3.25M — down 31% from $4.71M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new APTO positions and 3 closed out — a net gain of 1 holder — while 3 added to existing stakes and 4 trimmed.
The largest buyer was Sigma Planning Corp, opening a new position worth an estimated $573K. The largest seller was Goldman Sachs, exiting entirely with an estimated $165K sold.
- 25 institutional investors held Aptose Biosciences, Inc. (APTO) as of Q3 2023, up from 24 in Q2 2023.
- Funds reported $3.25M of Aptose Biosciences, Inc. stock for Q3 2023, down 31% quarter-over-quarter.
- 4 funds opened new Aptose Biosciences, Inc. positions in Q3 2023 and 3 closed out, a net change of +1 holder.
- The largest Aptose Biosciences, Inc. buyer in Q3 2023 was Sigma Planning Corp, an estimated $573K added.
- The largest Aptose Biosciences, Inc. seller in Q3 2023 was Goldman Sachs, an estimated $165K sold.
Based on aggregated 13F filings for Q3 2023.